It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IBM’s FA Score shows that 2 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IBM’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 4 bullish TA indicator(s).
IBM (@Information Technology Services) experienced а -3.07% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -0.76% for the same time period.
The average weekly price growth across all stocks in the @Information Technology Services industry was +15.67%. For the same industry, the average monthly price growth was +9.14%, and the average quarterly price growth was +20.51%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.54%. For the same industry, the average monthly price growth was +3.41%, and the average quarterly price growth was +6.08%.
IBM is expected to report earnings on Oct 21, 2026.
JNJ is expected to report earnings on Oct 20, 2026.
The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.
@Pharmaceuticals: Major (-0.54% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| IBM | JNJ | IBM / JNJ | |
| Capitalization | 217B | 651B | 33% |
| EBITDA | 17.6B | 34B | 52% |
| Gain YTD | -20.815 | 32.565 | -64% |
| P/E Ratio | 20.41 | 31.32 | 65% |
| Revenue | 69.1B | 97.9B | 71% |
| Total Cash | N/A | 3.24B | - |
| Total Debt | 65.3B | 49B | 133% |
IBM | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 49 | 4 | |
SMR RATING 1..100 | 29 | 37 | |
PRICE GROWTH RATING 1..100 | 52 | 18 | |
P/E GROWTH RATING 1..100 | 93 | 11 | |
SEASONALITY SCORE 1..100 | 48 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IBM's Valuation (8) in the Information Technology Services industry is in the same range as JNJ (12) in the Pharmaceuticals Major industry. This means that IBM’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for IBM (49) in the Information Technology Services industry. This means that JNJ’s stock grew somewhat faster than IBM’s over the last 12 months.
IBM's SMR Rating (29) in the Information Technology Services industry is in the same range as JNJ (37) in the Pharmaceuticals Major industry. This means that IBM’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for IBM (52) in the Information Technology Services industry. This means that JNJ’s stock grew somewhat faster than IBM’s over the last 12 months.
JNJ's P/E Growth Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for IBM (93) in the Information Technology Services industry. This means that JNJ’s stock grew significantly faster than IBM’s over the last 12 months.
| IBM | JNJ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 61% | 1 day ago 45% |
| Stochastic ODDS (%) | 1 day ago 56% | 1 day ago 47% |
| Momentum ODDS (%) | 1 day ago 59% | 1 day ago 34% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 36% |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 41% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 50% |
| Advances ODDS (%) | 8 days ago 66% | 2 days ago 46% |
| Declines ODDS (%) | 28 days ago 54% | 28 days ago 42% |
| BollingerBands ODDS (%) | N/A | 1 day ago 29% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 51% |
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.